Tenecteplase-Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke with Proven Occlusion

Stroke

Volumn 46, Issue 3, 2015, Pages 769-774

  Coutts, Shelagh B ^a,b   Dubuc, Véronique ^a   Mandzia, Jennifer ^a   Kenney, Carol ^a   Demchuk, Andrew M ^a,b   Smith, Eric E ^a,b   Subramaniam, Suresh ^a   Goyal, Mayank ^a,b   Patil, Shivanand ^a   Menon, Bijoy K ^a,b   Barber, Philip A ^a,b   Dowlatshahi, Dar ^c   Field, Thalia ^d   Asdaghi, Negar ^d   Camden, Marie Christine ^e   Hill, Michael D ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

Ischemic attack; Stroke; Therapeutic thrombolysis; Tomography; Transient; X ray computed

Indexed keywords

TENECTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AIRWAY OBSTRUCTION; ANGIONEUROTIC EDEMA; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN FUNCTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EVALUATION STUDY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RECANALIZATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; CANADA; CLINICAL TRIAL; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; PROCEDURES; STROKE;

AGED; BRAIN ISCHEMIA; CANADA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84929288219     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.008504     Document Type: Article

References (30)

1. Reeves M, Khoury J, Alwell K, Moomaw C, Flaherty M, Woo D, et al. Distribution of National Institutes of Health stroke scale in the Cincinnati/Northern Kentucky Stroke Study. Stroke. 2013;44:3211-3213. doi: 10.1161/STROKEAHA.113.002881.
2. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, et al; Neuroscience Institute. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004;35:e27-e29. doi: 10.1161/01. STR.0000109767.11426.17.
3. Smith EE, Fonarow GC, Reeves MJ, Cox M, Olson DM, Hernandez AF, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke. 2011;42:3110-3115. doi: 10.1161/STROKEAHA.111.613208.
4. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
5. Nedeltchev K, Schwegler B, Haefeli T, Brekenfeld C, Gralla J, Fischer U, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke. 2007;38:2531-2535. doi: 10.1161/STROKEAHA.107.482554.
6. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005;36:2497-2499. doi: 10.1161/01. STR.0000185798.78817.f3.
7. Rajajee V, Kidwell C, Starkman S, Ovbiagele B, Alger JR, Villablanca P, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology. 2006;67:980-984. doi: 10.1212/01. wnl.0000237520.88777.71.
8. Kim JT, Park MS, Chang J, Lee JS, Choi KH, Cho KH. Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke. PLoS One. 2013;8:e70996. doi: 10.1371/journal.pone.0070996.
9. Coutts SB, Modi J, Patel SK, Demchuk AM, Goyal M, Hill MD; Calgary Stroke Program. CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: results of the prospective CATCH study. Stroke. 2012;43:1013-1017. doi: 10.1161/STROKEAHA.111.637421.
10. Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The assent-2 double-blind randomised trial. Lancet. 1999;354:716-722.
11. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41:1229-1245. doi: 10.2165/00003088-200241150-00001.
12. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099-1107. doi: 10.1056/NEJMoa1109842.
13. TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion (TEMPO-1) clinical trial listing. Clinical trials.gov Web site. https://www. Clinicaltrials. Gov/ct2/show/nct01654445. Accessed January 1, 2015.
14. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. doi: 10.1016/S0140-6736 (07) 60149-4.
15. Larrue V, von Kummer R R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438-441.
16. Tissue Plasminogen Activator for Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
17. Coutts SB, Hill MD, Campos CR, Choi YB, Subramaniam S, Kosior JC, et al; VISION Study Group. Recurrent events in transient ischemic attack and minor stroke: what events are happening and to which patients? Stroke. 2008;39:2461-2466. doi: 10.1161/STROKEAHA.107.513234.
18. Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989;45:925-937.
19. Lindsay P, Bayley M, McDonald A, Graham ID, Warner G, Phillips S. Toward a more effective approach to stroke: Canadian Best Practice Recommendations for Stroke Care. CMAJ. 2008;178:1418-1425. doi: 10.1503/cmaj.071253.
20. Sato S, Uehara T, Ohara T, Suzuki R, Toyoda K, Minematsu K; Stroke Unit Multicenter Observational (SUMO) Study Investigators. Factors associated with unfavorable outcome in minor ischemic stroke. Neurology. 2014;83:174-181. doi: 10.1212/WNL.0000000000000572.
21. Coutts SB, Modi J, Patel SK, Aram H, Demchuk AM, Goyal M, et al. What causes disability after transient ischemic attack and minor stroke?: Results from the CT and MRI in the Triage of TIA and minor Cerebrovascular Events to Identify High Risk Patients (CATCH) Study. Stroke. 2012;43:3018-3022. doi: 10.1161/STROKEAHA.112.665141.
22. Coutts SB, Lindley RI, Hill MD, Cohen G, J. M. W, Sandercock P, et al. Effect of thrombolysis in a minor stroke population. Analysis of minor stroke patients treated in the ist-3 study. Cerebrovasc Dis. 2014;37:156.
23. Mishra SM, Dykeman J, Sajobi TT, Trivedi A, Almekhlafi M, Sohn SI, et al. Early reperfusion rates with IV tPA are determined by CTA clot characteristics. AJNR Am J Neuroradiol. 2014;35:2265-2272. doi: 10.3174/ajnr. A4048.
24. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935. doi: 10.1016/S0140-6736 (14) 60584-5.
25. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993;342:1523-1528.
26. Zinkstok SM, Engelter ST, Gensicke H, Lyrer PA, Ringleb PA, Artto V, et al. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke. 2013;44:1080-1084. doi: 10.1161/STROKEAHA.111.000126.
27. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM; TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36:607-612. doi: 10.1161/01. STR.0000154872.73240.e9.
28. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707-711. doi: 10.1161/STROKEAHA.109.572040.
29. Coutts SB, Wein TH, Lindsay MP, Buck B, Cote R, Ellis P, et al. Canadian Stroke Best Practice Recommendations: secondary prevention of stroke guidelines, update 2014 [published online ahead of print December 23, 2014]. Int J Stroke. http://onlinelibrary.wiley.com/doi/10.1111/ijs.12439/full. Accessed January 1, 2015.
30. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20. doi: 10.1056/NEJMoa1411587.